AndroGel Cost in Nevada 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is the Cash Price of AndroGel in Nevada in 2026?

The retail cash price for a 30-day supply of AndroGel 1.62% at Nevada pharmacies sits at roughly $510 per month in 2026, which matches AbbVie's current wholesale acquisition cost. That figure applies at major chains including Walgreens, CVS, and Smith's Food and Drug locations across Las Vegas, Reno, and Henderson. Prices vary slightly by pharmacy and by whether a GoodRx or similar coupon is applied.

Generic testosterone gel (1% and 1.62% formulations) is available at some Nevada pharmacies for $180 to $270 per month without insurance, depending on the dispenser. The FDA granted approval to multiple generic manufacturers following the expiration of key AndroGel patents, giving patients at least one lower-cost brand-name alternative at retail. FDA orange book listings confirm generic testosterone gel approvals.

Hypogonadism affects roughly 2 to 6 million men in the United States, and testosterone replacement therapy is the standard of care when two morning serum testosterone levels fall below the laboratory reference range (typically <300 ng/dL), according to the American Urological Association guideline. The AUA 2018 guideline on testosterone deficiency states that "testosterone therapy is indicated for symptomatic men with consistently low serum testosterone concentrations." Confirming the diagnosis before starting therapy protects patients and satisfies most insurance prior-authorization requirements in Nevada.

GoodRx codes can reduce the out-of-pocket cost to between $140 and $210 for generic testosterone gel 1.62% at select Nevada pharmacies. Always verify the specific pharmacy's participation before presenting the coupon at the counter.

Does Nevada Medicaid Cover AndroGel?

Nevada Medicaid does not cover branded AndroGel or its generic equivalents for male hypogonadism on the current Nevada Medicaid preferred drug list. The Nevada Division of Health Care Financing and Policy maintains a drug exclusion list that places testosterone gel formulations outside covered benefits for the adult male hypogonadism indication in most managed care organization contracts under Nevada Check Up and Nevada Medicaid.

Patients enrolled in Nevada Medicaid who require testosterone replacement should ask their provider about intramuscular testosterone cypionate injections, which appear on the Nevada Medicaid preferred drug list at a substantially lower cost than topical formulations. Testosterone cypionate 200 mg/mL vials are typically covered with prior authorization under the standard endocrine drug tier. NCBI's coverage analysis of testosterone formulations in Medicaid programs documents the widespread restriction of topical androgens in state Medicaid formularies across the United States.

An exception process exists. Providers may submit a prior authorization request to Nevada Medicaid if a patient has a documented medical contraindication to injections (for example, a bleeding disorder or needle phobia documented in the medical record). Approval rates for such exceptions in Nevada are low but not zero. The request must include two confirmatory testosterone lab values, documented symptoms of hypogonadism, and a clinical explanation of why the injectable route is not appropriate.

Nevada Medicaid dual eligibles (who also carry Medicare Part D) may have different formulary access depending on the specific Part D plan. Medicare Part D covers testosterone gel under the pharmacy benefit when the prescriber documents medical necessity, though prior authorization and quantity limits apply.

Which Commercial Insurance Plans Cover AndroGel in Nevada?

Major commercial insurers operating in Nevada, including Anthem Blue Cross Blue Shield, Aetna, UnitedHealthcare, Cigna, and the Nevada Health CO-OP, generally place testosterone gel on Tier 3 or Tier 4 of their drug formularies. That means a 30-day copay ranging from $60 to $180 after the deductible is met, depending on plan design.

Prior authorization is nearly universal across Nevada commercial plans for AndroGel and generic testosterone gel. Standard requirements include:

• Two morning serum total testosterone values below 300 ng/dL drawn at least one week apart
• Documentation of at least two symptoms consistent with hypogonadism (low libido, fatigue, reduced muscle mass, depressed mood)
• Confirmation that the patient is not currently using anabolic steroids for non-medical purposes
• For patients younger than 40, documentation that secondary causes of low testosterone (pituitary adenoma, Klinefelter syndrome) have been evaluated

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy specifies that clinicians "should prescribe testosterone therapy only to men with classical androgen deficiency syndromes," which directly mirrors the prior-authorization criteria Nevada insurers require.

Step therapy is common. Several Nevada Anthem and UnitedHealthcare plans require a trial of generic testosterone gel before approving branded AndroGel. If the generic is tolerated but ineffective at standard doses, a prescriber can submit a step-therapy exception with clinical notes.

Employer-sponsored self-insured plans (which cover a large portion of Nevada workers in the gaming and hospitality sectors) follow their own formularies and may differ from the above. A specialty pharmacy call to the plan's pharmacy benefit manager (PBM) before the first fill confirms current formulary tier and prior-authorization requirements.

How Does the AbbVie Savings Card Work in Nevada?

AbbVie's myAbbVie Assist savings program offers commercially insured patients a copay card that may reduce the monthly out-of-pocket cost of AndroGel 1.62% to as little as $0 per month, subject to program terms. Eligibility requires that the patient be covered by a commercial (private) insurance plan. Patients on Medicare, Medicaid, TRICARE, or any other federal or state government insurance program are not eligible.

Nevada patients can enroll online at the AbbVie patient assistance portal or by calling 1-800-222-6885. The card covers the gap between the insurance copay and the full cash price, up to an annual maximum benefit. AbbVie periodically adjusts the annual cap, so verifying the current cap at the time of enrollment is necessary.

For uninsured Nevada patients who do not qualify for the copay card, AbbVie's myAbbVie Assist patient assistance program provides branded AndroGel at no charge to patients meeting income eligibility criteria (generally household income at or below 400 percent of the federal poverty level). Documentation of income and lack of insurance coverage is required. Processing time is typically 2 to 4 weeks.

The FDA's approved prescribing information for AndroGel 1.62% confirms the approved dosing range of 40.5 mg to 81 mg once daily and the boxed warning regarding secondary exposure risk, which prescribers in Nevada must review with patients before initiating therapy.

Is Compounded Testosterone Gel Legal in Nevada?

Yes. Compounded testosterone gel is legal in Nevada when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound medications for individual patients based on a valid prescription from a licensed prescriber. Nevada has multiple licensed 503A compounding pharmacies, and patients can also use out-of-state 503A pharmacies that ship to Nevada under federal law.

The price difference is significant. Compounded testosterone gel typically costs $90 to $120 per month from a Nevada or Nevada-accepting 503A compounding pharmacy, compared to the $510 list price for branded AndroGel. The active pharmaceutical ingredient (testosterone USP) is identical; the vehicle, preservatives, and concentration may differ.

FDA guidance on 503A compounding pharmacies outlines the conditions under which compounded testosterone preparations are legal, including the requirement for a patient-specific prescription and a licensed prescriber-patient relationship.

Section 503B outsourcing facilities may also compound testosterone gel in larger quantities for use in clinical settings, but these are primarily used by clinics rather than individual retail patients.

A critical clinical note: compounded preparations are not FDA-approved, meaning they have not undergone the same manufacturing consistency reviews as AndroGel. Absorption can vary between compounders. Patients switching from branded to compounded testosterone gel should have serum testosterone checked 4 to 6 weeks after the transition to confirm therapeutic levels. A peer-reviewed comparison of testosterone gel absorption variability found clinically meaningful inter-individual differences in skin absorption that affect steady-state serum levels.

What Clinical Evidence Supports Testosterone Gel Therapy?

The strongest evidence base for testosterone replacement therapy in older men with confirmed hypogonadism comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials conducted across 12 sites in the United States (N=790 men, age 65 or older, serum testosterone <275 ng/dL). Published in the New England Journal of Medicine in 2016, the Sexual Function Trial within TTrials found that testosterone treatment increased sexual activity and sexual desire compared to placebo at 12 months [1]. The Vitality Trial found a statistically significant improvement in sexual desire (P<0.001) but a modest and not clearly significant improvement in energy and fatigue.

The Physical Function Trial within TTrials found that testosterone gel did not significantly improve walking distance at 12 months, though secondary measures of leg strength improved. Bone mineral density increased significantly in the Bone Trial (lumbar spine BMD increased 7.5% vs. 0.6% placebo) [1].

The Endocrine Society guideline update summarizes TTrials findings: "In men 65 years or older with unequivocally low testosterone levels, testosterone treatment for 1 year increased bone density and estimated bone strength." The guideline recommends against prescribing testosterone to men with age-related decline in testosterone who do not have a classical hypogonadism syndrome.

Cardiovascular safety remains an area of active study. The TRAVERSE trial (N=5,246, mean age 57) evaluated cardiovascular outcomes in men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. Published in 2023 in the New England Journal of Medicine, TRAVERSE found that testosterone replacement was noninferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [2]. PubMed TRAVERSE trial record confirms a MACE hazard ratio of 0.96 (96% CI 0.78 to 1.17), which fell within the prespecified noninferiority margin.

The FDA updated the AndroGel prescribing label in 2015 to add a warning regarding venous thromboembolism risk and to require labeling about the potential for cardiovascular events. The FDA drug safety communication from 2015 states: "We have concluded that there is a possible increased cardiovascular risk associated with testosterone use." Prescribers in Nevada should review this communication with patients as part of informed consent.

Hematocrit elevation is the most common dose-dependent adverse effect of testosterone gel, occurring in roughly 5 to 10 percent of treated men. A systematic review of testosterone therapy adverse effects found that hematocrit exceeded 54 percent in approximately 4 percent of testosterone-treated men versus 1 percent of placebo recipients. Nevada prescribers should check hematocrit at baseline, 3 months, and annually thereafter.

Can I Get an AndroGel Prescription via Telehealth in Nevada?

Telehealth prescribing of testosterone gel is permitted in Nevada for established telehealth platforms that maintain a synchronous audio-video visit and a documented prescriber-patient relationship. Nevada Revised Statutes Chapter 630 governs medical practice and does not prohibit controlled substance prescribing via telehealth when the provider meets the standard of care requirements.

The Ryan Haight Online Pharmacy Consumer Protection Act requires that a prescribing provider conduct at least one in-person examination before prescribing a controlled substance via telemedicine, unless a DEA-registered telemedicine practice or a qualifying public health emergency exception applies. The DEA's proposed telemedicine prescribing rules (published in 2023) would allow ongoing telemedicine prescribing of Schedule III controlled substances (which includes testosterone) for established patients who had an initial in-person visit with any DEA-registered provider. DEA telemedicine prescribing information outlines the current regulatory framework.

In practical terms, many Nevada-based men obtain testosterone prescriptions through telehealth TRT clinics that either (a) have patients complete an initial in-person lab draw and video visit, or (b) operate under the current DEA special registration framework for telemedicine. HealthRX connects Nevada patients with board-certified providers who order the required labs (two morning total testosterone, LH, FSH, complete blood count, PSA for men over 40, estradiol, and metabolic panel), review results, and prescribe by video visit when clinically appropriate.

The HealthRX Nevada TRT intake protocol requires two confirmatory testosterone lab draws collected before 10 AM on separate days, PSA screening for men 40 and older, hematocrit baseline, and a documented discussion of the FDA boxed warning on secondary exposure before the first prescription is sent electronically to a Nevada or mail-order pharmacy.

What Is the Cheapest Way to Get Testosterone Gel in Nevada?

The lowest-cost legal path for a Nevada man who needs testosterone gel depends on his insurance status.

For commercially insured patients, using the AbbVie copay card alongside a Tier 3 formulary plan may bring the monthly cost to $0 to $30. Generic testosterone gel on a preferred tier can cost $60 to $90 per month after meeting the deductible.

For uninsured patients, compounded testosterone gel from a licensed 503A pharmacy is typically the most affordable option at $90 to $120 per month. A telehealth visit to establish the prescription adds a one-time or monthly fee of $75 to $150 depending on the platform, but this is offset within the first 2 to 3 months compared to cash-pay branded AndroGel.

A pharmacoeconomic analysis of testosterone replacement formulations found that injectable testosterone cypionate remains the lowest-cost option at $20 to $40 per month for drug costs alone, though patients must factor in injection supplies or clinic visit fees.

GoodRx and similar discount programs can reduce generic testosterone gel to $140 to $210 per month at Nevada retail pharmacies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed generic testosterone gel 1.62% at approximately $38 for 150 packets as of mid-2025, though availability at Nevada retail locations varies.

The AACE clinical practice guidelines for hypogonadism note that formulation choice should account for patient preference, cost, and adherence, since adherence to daily topical application is lower than adherence to every-2-week injections in some populations.

Secondary Exposure Risk: What Nevada Patients and Families Must Know

The FDA boxed warning on all testosterone gel products addresses secondary (inadvertent) exposure to testosterone gel by women and children. FDA prescribing information for testosterone topical gels documents cases of virilization in children who had skin-to-skin contact with men using testosterone gel, including premature pubic hair, clitoral or penile enlargement, and advanced bone age.

Nevada patients must apply AndroGel to the shoulders and upper arms only (not the genitals or abdomen for 1.62% formulation), allow the gel to dry for at least 3 to 5 minutes, and cover the application site with clothing before contact with children or women. Washing the application site with soap and water before anticipated contact provides additional protection. A published case series of secondary testosterone exposure in children described eight pediatric cases linked to household testosterone gel use, all of which resolved after discontinuation of exposure.